Zepto Life Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Zepto Life Technology is a private, commercial-stage diagnostics company leveraging a proprietary Giant Magnetoresistance (GMR) biosensor platform to enable highly sensitive and multiplexed molecular testing. The company has a dual business model, combining the development of its own diagnostic assays (e.g., the Fungiflex® Mold Panel) with service offerings through its high-complexity CLIA lab and Clinical Research Organization (CRO) unit. With a leadership team strong in diagnostics and engineering, and a prestigious Medical & Technical Advisory Board, Zepto is positioned to address unmet needs in infectious disease diagnostics with rapid, precise testing solutions.

Infectious Diseases

Technology Platform

Proprietary molecular diagnostics platform based on Giant Magnetoresistance (GMR) biosensors. Utilizes nanomagnetic particle labels and on-chip bio-surface technology for highly sensitive, multiplexed, and rapid detection of target analytes from minimally invasive samples.

Opportunities

The global demand for rapid, sensitive, and multiplexed molecular diagnostics, especially in complex infectious diseases like invasive fungal infections, represents a significant growth opportunity.

The platform's underlying technology is also potentially applicable to other high-value areas such as sepsis, oncology, and STI testing, allowing for pipeline expansion.

Risk Factors

Key risks include the challenge of commercializing a novel diagnostic technology against entrenched competitors, the lengthy and uncertain regulatory pathway for FDA clearance, and the difficulty of securing favorable insurance reimbursement for new tests.

Competitive Landscape

Zepto competes in the crowded molecular diagnostics market against large, established players (e.g., Roche, BioFire/BioMérieux) and numerous startups. Its differentiation hinges on the claimed superior sensitivity and speed of its GMR-based platform, particularly for multiplex fungal detection, a specialized and challenging diagnostic niche.

More companies in Diagnostics & Precision Medicine →More companies in United States →